Chemosensitivity of various peritoneal cancer cell lines to HIPEC and PIPAC: comparison of an experimental duplex drug to standard drug regimens in vitro
- 175 Downloads
We performed an in-vitro study testing the chemosensitivity of peritoneal cancer cell lines (SW620, HCT116, MKN45, 23,132/87, OAW42) to various cytostatic drug regimens. A duplex drug, characterized by reversible linking of the antimetabolites 2′-deoxy-5-fluorouridine (5-FdU) and 3’-C-ethynylcytidine (ECyd), was compared to oxaliplatin or to cisplatin plus doxorubicin. The experiments were designed to reflect the conditions of intraperitoneal chemotherapy. CASY® (Cell Analysis System) technology was used to compare the impact of incubation temperature/duration and drug concentration on the viability of the cancer cell lines versus normal human dermal fibroblasts. Two incubation scenarios were explored: (i) hyperthermic intraperitoneal chemotherapy (HIPEC) with 1 h of incubation at 42 °C, and (ii) pressurized intraperitoneal aerosol chemotherapy (PIPAC) with several successive incubations at 37 °C. Under HIPEC conditions, oxaliplatin induced a potent temperature-dependent growth inhibition of colon cancer cells not seen with the duplex drug. Under PIPAC conditions, the duplex drug achieved the same growth inhibition at a fraction of the dose level required with oxaliplatin. Gastric and ovarian cancer cells were more sensitive to cisplatin plus doxorubicin than to the duplex drug under PIPAC conditions. The duplex drug suggests itself, notably in cases of platinum resistance, as an alternative or addition to intraperitoneal chemotherapies when platinum-based PIPAC technology is used. Using it with HIPEC technology is not recommended. Higher doses of the duplex drug will enhance growth inhibition, albeit at the cost of a severely reduced difference in chemosensitivity between tumor and normal cells. Our findings provide orientation for PIPAC-based personalized intraperitoneal chemotherapy.
KeywordsChemosensitivity PIPAC HIPEC Peritoneal cancer cell lines Platinum versus duplex drug
Compliance with ethical standards
Conflict of interest
All authors declare no conflict of interest.
All procedures were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
- 2.Franko J, Shi Q, Meyers JP, Maughan TS, Adams RA, Seymour MT, Saltz L, Punt CJA, Koopman M, Tournigand C, Tebbutt NC, Diaz-Rubio E, Souglakos J, Falcone A, Chibaudel B, Heinemann V, Moen J, De Gramont A, Sargent DJ, Grothey A, Analysis, research in cancers of the digestive system G (2016) Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. Lancet Oncol 17(12):1709–1719. https://doi.org/10.1016/S1470-2045(16)30500-9 CrossRefPubMedGoogle Scholar
- 6.Marques RP, Duarte GS, Sterrantino C, Pais HL, Quintela A, Martins AP, Costa J (2017) Triplet (FOLFOXIRI) versus doublet (FOLFOX or FOLFIRI) backbone chemotherapy as first-line treatment of metastatic colorectal cancer: a systematic review and meta-analysis. Crit Rev Oncol Hematol 118:54–62. https://doi.org/10.1016/j.critrevonc.2017.08.006 CrossRefPubMedGoogle Scholar
- 7.Kang BW, Kim TW, Lee JL, Ryu MH, Chang HM, Yu CS, Kim JC, Kim JH, Kang YK, Lee JS (2009) Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysis. Med Oncol 26(1):32–37. https://doi.org/10.1007/s12032-008-9077-8 CrossRefPubMedGoogle Scholar
- 10.Harter P, Muallem ZM, Buhrmann C, Lorenz D, Kaub C, Hils R, Kommoss S, Heitz F, Traut A, du Bois A (2011) Impact of a structured quality management program on surgical outcome in primary advanced ovarian cancer. Gynecol Oncol 121(3):615–619. https://doi.org/10.1016/j.ygyno.2011.02.014 CrossRefPubMedGoogle Scholar
- 11.Stuart GC, Kitchener H, Bacon M, duBois A, Friedlander M, Ledermann J, Marth C, Thigpen T, Trimble E, Participants of 4th ovarian Cancer consensus C, Gynecologic Cancer I (2011) 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer 21(4):750–755. https://doi.org/10.1097/IGC.0b013e31821b2568 CrossRefPubMedGoogle Scholar
- 16.Herman TS, Teicher BA, Cathcart KN, Kaufmann ME, Lee JB, Lee MH (1988) Effect of hyperthermia on cis-diamminedichloroplatinum(II) (rhodamine 123)2[tetrachloroplatinum(II)] in a human squamous cell carcinoma line and a cis-diamminedichloroplatinum(II)-resistant subline. Cancer Res 48(18):5101–5105PubMedGoogle Scholar
- 19.van de Vaart PJ, van der Vange N, Zoetmulder FA, van Goethem AR, van Tellingen O, ten Bokkel Huinink WW, Beijnen JH, Bartelink H, Begg AC (1998) Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines. Eur J Cancer 34(1):148–154CrossRefPubMedGoogle Scholar
- 22.Sukovas A, Cesna V, Jasukaitiene A, Barauskas G, Nadisauskiene RJ, Dambrauskas Z, Paskauskas S, Gulbinas A (2017) Response of OVCAR-3 cells to cisplatin and hyperthermia: does hyperthermia really matter? Anticancer Res 37(9):5011–5018. https://doi.org/10.21873/anticanres.11915 PubMedCrossRefGoogle Scholar
- 23.Girshally R, Demtroder C, Albayrak N, Zieren J, Tempfer C, Reymond MA (2016) Pressurized intraperitoneal aerosol chemotherapy (PIPAC) as a neoadjuvant therapy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World J Surg Oncol 14(1):253. https://doi.org/10.1186/s12957-016-1008-0 CrossRefPubMedPubMedCentralGoogle Scholar
- 24.Dueckelmann AM, Fink D, Harter P, Heinzelmann V, Marth C, Mueller M, Reinthaller A, Tamussino K, Wimberger P, Sehouli J (2018) The use of PIPAC (pressurized intraperitoneal aerosol chemotherapy) in gynecological oncology: a statement by the German "Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR)", the Swiss and Austrian AGO, and the north-eastern German Society of Gynaecologic Oncology. Arch Gynecol Obstet 297(4):837–846. https://doi.org/10.1007/s00404-018-4673-0 CrossRefPubMedGoogle Scholar
- 25.Schott H, Schott S, Schwendener RA (2009) Synthesis and in vitro activities of new anticancer duplex drugs linking 2′-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) via a phosphodiester bonding. Bioorg Med Chem 17(19):6824–6831. https://doi.org/10.1016/j.bmc.2009.08.033 CrossRefPubMedGoogle Scholar
- 26.Weinreich J, Schott S, Königsrainer I, Zieker D, Königsrainer A, Schott H (2011) Cytostatic activity of the duplex drug linking 2′-deoxy-5-fluorouridine (5FdU) with 3'-C-ethynylcytidine (ECyd) against gastric adenocarcinoma cell lines. Investig New Drugs 29(6):1294–1302. https://doi.org/10.1007/s10637-010-9483-6 CrossRefGoogle Scholar
- 27.Schott S, Wimberger P, Klink B, Grutzmann K, Puppe J, Wauer US, Klotz DM, Schrock E, Kuhlmann JD (2017) The conjugated antimetabolite 5-FdU-ECyd and its cellular and molecular effects on platinum-sensitive vs. -resistant ovarian cancer cells in vitro. Oncotarget 8(44):76935–76948. https://doi.org/10.18632/oncotarget.20260 CrossRefPubMedPubMedCentralGoogle Scholar
- 28.Beaufort CM, Helmijr JC, Piskorz AM, Hoogstraat M, Ruigrok-Ritstier K, Besselink N, Murtaza M, van IWF, Heine AA, Smid M, Koudijs MJ, Brenton JD, Berns EM, Helleman J (2014) Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes. PLoS One 9(9):e103988. https://doi.org/10.1371/journal.pone.0103988 CrossRefPubMedPubMedCentralGoogle Scholar
- 29.Lincet H, Guével B, Pineau C, Allouche S, Lemoisson E, Poulain L, Gauduchon P (2012) Comparative 2D-DIGE proteomic analysis of ovarian carcinoma cells: toward a reorientation of biosynthesis pathways associated with acquired platinum resistance. J Proteome 75(4):1157–1169. https://doi.org/10.1016/j.jprot.2011.10.030 CrossRefGoogle Scholar
- 32.Winkelmeier P, Glauner B, Lindl T (1993) Quantification of cytotoxicity by cell volume and cell proliferation. ATLA 21:269–280Google Scholar
- 33.de Bree E, Michelakis D, Stamatiou D, Romanos J, Zoras O (2017) Pharmacological principles of intraperitoneal and bidirectional chemotherapy. Pleura and Peritoneum 2(2):47–62Google Scholar